Evidence map›Paper›PMID 17496204›Full record

ReviewBlood2007

Trousseau's syndrome: multiple definitions and multiple mechanisms.

Ajit Varki

Open access · bronzeAbstract readReview
In one paragraph

Review in Blood, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 368 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
368citing papers in PubMed, 4 pooled it
20.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

368 citing papers in PubMed, 4 syntheses or guidelines pooled it, 820 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Recurrent embolic stroke associated with adenomyosis: A single case report and literature review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

308 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ajit VarkiUniversity of California, San Diego, La Jolla CA 92093-0687, USA. a1varki@ucsd.edu
University of California, San Diego · US

Funding

Siglec Modulation of Inflammation in Humans and MiceP01HL057345 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, NISSI MARY · 1997 to 2012
$24.1M
SULFATED OLIGOSACCHARIDES OF NORMAL AND MALIGNANT CELLSR01CA038701 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, AJIT P · 1985 to 2015
$5.5M
NCI NIH HHS CA38701NCI NIH HHS R01 CA038701NHLBI NIH HHS HL057345NHLBI NIH HHS P01 HL057345
6 · The paper itself

Abstract

In 1865, Armand Trousseau noted that unexpected or migratory thrombophlebitis could be a forewarning of an occult visceral malignancy. An analysis by Sack and colleagues in 1977 extended the term Trousseau's syndrome to include chronic disseminated intravascular coagulopathy associated with microangiopathy, verrucous endocarditis, and arterial emboli in patients with cancer, often occurring with mucin-positive carcinomas. In recent times the term has been ascribed to various clinical situations, ranging all the way from these classic descriptions to any kind of coagulopathy occurring in the setting of any kind of malignancy. These multiple definitions of Trousseau's syndrome are partly the consequence of multiple pathophysiologic mechanisms that apparently contribute to the hypercoagulability associated with cancer. Even the classic syndrome probably represents a spectrum of disorders, ranging from exaggerated fluid-phased thrombosis dependent on prothrombotic agents such as tissue factor to a platelet- and endotheliumum-based selectin-dependent microangiopathy associated with mucin-producing carcinomas, along with thrombin and fibrin production. Also considered here are recent hypotheses about genetic pathways within tumor cells that might trigger these thrombotic phenomena, and the reasons why therapy with heparins of various kinds remain the preferred treatment, probably because of their salutary actions on several of the proposed pathologic mechanisms.

Indexed as

Terminology as TopicAnimalsDisseminated Intravascular CoagulationEmbolismEndocarditisHumansNeoplasmsSyndromeThrombosis

Identifiers

PMID17496204
PMCPMC1976377
OpenAlexW2155066067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.